UF researcher receives NCI grant to study novel therapeutic strategies for renal cancer
The study will provide a rationale for targeting BCL-XL for cancer immunotherapy treatment for renal cell carcinomas.
The study will provide a rationale for targeting BCL-XL for cancer immunotherapy treatment for renal cell carcinomas.
The study involves describing the discovery of a novel small molecule, biisoquinolinederivative (DH20931).
The study will evaluate the potential of AB-free kava against tobacco smoke-induced lung cancer.
Padraic O'Mally, M.D., will lead the Division of Urologic Oncology in all aspects including clinical, education and research.
The grant will fund a phase I/II clinical trial for malignant pediatric gliomas using 8R-70CAR T cells.
Jiang Bian, Ph.D., director of the Cancer Informatics Shared Resource at the Cancer Center, is making UF Health’s IT infrastructure “AI ready.”
The study will focus on understanding the role of DAXX in triple negative breast cancer.
The UF Health Cancer Center's Research Day 2023 on Jan. 11 drew a record number of submissions as the event returned to an in-person format.
The study aims to define the impact of the proteomic and metabolomic landscape of leukemic cells on patient risk and therapeutic outcome.
The UF Health Cancer Center will be presenting at the 2023 ASCO Gastrointestinal Cancers Symposium.